Shares of Gilead Sciences Inc. rose after the company’s antiviral drug remdesivir became the first approved treatment for Covid-19 in the United States.
Shares of Gilead Sciences jumped in trading following full approval for Veklury (remdesivir) as a treatment for Covid-19.
A row broke out over a World Health Organization (WHO) clinical trial which concluded that Gilead’s anti-viral drug remdesivir has little or no impact on a patient’s chances of surviving Covid-19.
Fujifilm Holdings Corp. said the company is seeking to have the flu drug Avigan approved in Japan as a treatment for Covid-19, a move that comes after a late-stage study showed reduced recovery times for patients with non-severe symptoms.
Gilead Sciences Inc.’s remdesivir had little or no effect on Covid-19 patients’ length of hospital stay or chances of survival, a clinical trial by the World Health Organization (WHO) found.
The European Union agreed to pay more than 1 billion euros ($1.2 billion) to Gilead for a six-month supply of the company’s antiviral drug remdesivir, shortly before the publication of final results for the largest trial of the Covid-19 medication.
In a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines, Covid-19 antibodies last at least three months and so do symptoms for many.
The U.S. National Institutes of Health is launching a clinical trial of a combination of Gilead Sciences’ antiviral drug remdesivir (Vitrakvy) and hyperimmune intravenous immunoglobulin (hIVIG).
Final data from Gilead Sciences Inc.’s antiviral drug remdesivir showed the treatment cut Covid-19 recovery time by five days compared with patients who got a placebo, one day faster than indicated in preliminary data, the company and researchers said.
Japan’s Takeda Pharmaceutical said on Friday an alliance of drugmakers the company spearheads enrolled the first patient in a global clinical trial of a blood plasma treatment for Covid-19 after months of regulatory delays.
